drugset / Trial / NCT07032727
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Timeline
- Start
- 2025-09-12
- Primary completion
- 2027-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Subcutaneous |
| Subject | Gilteritinib | Small molecule | — | Oral |
| Subject | Olutasidenib | Small molecule | — | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |
Indications
No indication recorded.